A review of standard and novel therapies in Crohn’s disease

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.10, Iss.7, 2000-07, pp. : 1021-1033

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Implications of Biological Therapies for Crohns Disease: Review of Infliximab

By Bodger Keith

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 875-888

Adis International

Access to resources Recommend Favorite

Novel therapy for Crohn’s disease targeting IL-6 signalling

By Ito Hiroaki

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 4, 2004-08 ,pp. : 287-294

Informa Healthcare

Access to resources Recommend Favorite

Therapy of Crohn’s disease in childhood

By Beattie R Mark Bremner A Ronald F

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 809-825

Informa Healthcare

Access to resources Recommend Favorite

TNF- antagonists for the treatment of Crohn’s disease

By Kam L.Y. Targan S.R.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 615-622

Informa Healthcare

Access to resources Recommend Favorite

Toxicity of infliximab in the course of treatment of Crohn’s disease

By Bratcher Jason M Korelitz Burton I

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 9-16

Informa Healthcare

Access to resources Recommend Favorite